Impact of Androgen Deprivation Therapy on Non-Alcoholic Fatty Liver Disease in Patients with Prostate Cancer : A CT Evaluation

© 2020 S. Karger AG, Basel..

PURPOSE: The aim of this study was to investigate the influence of androgen deprivation therapy (ADT) on the progression of non-alcoholic fatty liver disease (NAFLD) in patients with prostate cancer (PCa) by evaluation of hepatic steatosis on computed tomography (CT).

METHODS: The study included 77 PCa patients who underwent abdominal CT at baseline and after 6 months of ADT. The degree of hepatic steatosis was evaluated according to the attenuation value for liver parenchyma (CTLP), the attenuation ratio for liver and spleen (LSratio), and the difference in attenuation between LS (LSdif). The associations between these 3 indices and various metabolic syndrome-related factors were analyzed.

RESULTS: The number of NAFLD patients increased from 9 (11.6%) at baseline to 16 (20.7%) after ADT. The CTLP, LSratio, and LSdif values were significantly lower after ADT than before (p < 0.05). There were significant correlations between the percent change in CTLP and the percent change in HbA1c, between the percent change in LSratio and the percent change in abdominal circumference, and between the percent change in LSdif and the percent change in BMI.

CONCLUSIONS: Six months of ADT was associated with significant progression of NAFLD in PCa patients. This progression was strongly correlated with changes in HbA1c, abdominal circumference, and BMI.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:104

Enthalten in:

Urologia internationalis - 104(2020), 5-6 vom: 11., Seite 425-430

Sprache:

Englisch

Beteiligte Personen:

Sawazaki, Harutake [VerfasserIn]
Kitamura, Yosuke [VerfasserIn]
Yagi, Kota [VerfasserIn]
Arai, Yuichi [VerfasserIn]

Links:

Volltext

Themen:

Acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
Androgen deprivation therapy
Antineoplastic Agents, Hormonal
Computed tomography
EFY6W0M8TG
Journal Article
Leuprolide
Non-alcoholic fatty liver disease
Oligopeptides
Prostate cancer

Anmerkungen:

Date Completed 04.03.2021

Date Revised 04.03.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1159/000507351

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM309799732